ARTICLE | Clinical News
Brincidofovir: Phase III data
May 16, 2016 7:00 AM UTC
Next half, Chimerix plans to disclose final 36-week mortality data from AdVise. The company will not seek brincidofovir’s approval based on the AdVise data and instead intends to conduct a comparative...